Keyphrases
In Situ
100%
Therapeutic Response
100%
Fluorescence Imaging
100%
Cell Therapy
100%
Proteomics
100%
Drug Distribution
100%
Imaging Platform
100%
Drug Target
88%
Erlotinib
77%
Protein Expression
44%
Tumor
33%
Non-small Cell Lung Cancer (NSCLC)
33%
Intracellular Paired Agent Imaging
33%
Epidermal Growth Factor Receptor
22%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
22%
Spatial Context
22%
Cyclic Immunofluorescence
22%
Disease Progression
11%
Apoptosis
11%
Cancer Types
11%
Signaling Cascades
11%
Expression Profiling
11%
Oligo
11%
Oligonucleotides
11%
Pearson Correlation
11%
Overexpressing
11%
Molecular Targets
11%
Standard of Care
11%
Targeted Expression
11%
Tissue Sampling
11%
Tyrosine Kinase Inhibitor
11%
Epidermal Growth Factor Receptor Signaling
11%
Therapeutic Outcome
11%
Platinum-based Chemotherapy
11%
Pharmacokinetic Study
11%
Biomarker Testing
11%
Tyrosine Kinase Inhibitor Therapy
11%
Therapeutic Efficacy
11%
Small Molecule Drugs
11%
Analytical Tools
11%
Imaging Probe
11%
Cancer Tumor
11%
Pharmacodynamic Study
11%
Downstream Analysis
11%
Tumoral
11%
Expression Response
11%
Simultaneous Quantification
11%
Fluorescence Method
11%
Untargeted
11%
Conjugated Antibodies
11%
Imaging Assessment
11%
Cellular Biomarkers
11%
Biomarker Expression
11%
Protein Therapeutics
11%
Lung Cancer Model
11%
Sequential Imaging
11%
Proteomic Response
11%
Afatinib
11%
Proteomic Expression
11%
Osimertinib
11%
Spatial Proteomics
11%
High-dimensional Imaging
11%
Biochemistry, Genetics and Molecular Biology
Proteomics
100%
Optics
100%
Erlotinib
100%
Drug Distribution
100%
Epidermal Growth Factor Receptor
71%
Protein Expression
57%
Immunofluorescence
28%
Receptor Tyrosine Kinase Inhibitors
28%
Small Molecule
14%
Pharmacokinetics
14%
Monospecific Antibody
14%
Oligonucleotide
14%
Pharmacodynamics
14%
Tyrosine Kinase Inhibitor
14%
Drug Inhibition
14%
Afatinib
14%
Pharmacology, Toxicology and Pharmaceutical Science
Erlotinib
100%
Drug Distribution
100%
Neoplasm
57%
Epidermal Growth Factor Receptor
42%
Non Small Cell Lung Cancer
42%
Biological Marker
28%
Epidermal Growth Factor Receptor Kinase Inhibitor
28%
Combination Therapy
14%
Disease Exacerbation
14%
Disease
14%
Chemotherapy
14%
Malignant Neoplasm
14%
Cancer Model
14%
Pharmacodynamics
14%
Protein Tyrosine Kinase Inhibitor
14%
Pharmacokinetics
14%
Molecular Target
14%
Antibody Conjugate
14%
Oligonucleotide
14%
Afatinib
14%
Osimertinib
14%